Associated Papers
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
PIK3CA Mutations and Co-Mutations in Operated Non-Small Cell Lung Carcinoma.
Cokpinar S et al.
Journal of Clinical Medicine, 2024
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T et al.
Cancer Science, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M et al.
Cancers, 2024
Nrf2, A Target for Precision Oncology in Cancer Prognosis and Treatment.
Ngo HKC et al.
Journal of Cancer Prevention, 2023
Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer.
Boström M et al.
Nature Communications, 2022
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
Sumazin P et al.
Journal of Hepatology, 2022
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.
Berrino E et al.
Genome Medicine, 2022
High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.
Jiang X et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E et al.
International Journal of Molecular Sciences, 2021
Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J et al.
Frontiers in Oncology, 2021
Rare and common genetic variations in the Keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
Matana A et al.
Biochemical Pharmacology, 2020
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M et al.
Frontiers in Immunology, 2020
Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.
Kwon SM et al.
Scientific Reports, 2019
PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
Ji L et al.
Scientific Reports, 2019
A catalogue of somatic NRF2 gain-of-function mutations in cancer.
Kerins MJ et al.
Scientific Reports, 2018
Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.
Schuh A et al.
Cold Spring Harbor Molecular Case Studies, 2018
Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder.
Huppke P et al.
Nature Communications, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Longitudinal analysis of treatment-induced genomic alterations in gliomas.
Erson-Omay EZ et al.
Genome Medicine, 2017
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
Kim E et al.
Cancer Discovery, 2016